Edition:
India

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

3.27USD
22 Jun 2018
Change (% chg)

$0.20 (+6.51%)
Prev Close
$3.07
Open
$3.08
Day's High
$3.28
Day's Low
$3.02
Volume
123,860
Avg. Vol
34,491
52-wk High
$6.06
52-wk Low
$1.25

Chart for

About

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall... (more)

Overall

Beta: 0.88
Market Cap(Mil.): $27.98
Shares Outstanding(Mil.): 8.35
Dividend: --
Yield (%): --

Financials

BRIEF-Celsion Phase III Clinical Study Of Thermodox In Combination With Radiofrequency Ablation To Continue According To Protocol

* PHASE III CLINICAL STUDY OF THERMODOX IN COMBINATION WITH RADIOFREQUENCY ABLATION TO CONTINUE ACCORDING TO PROTOCOL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

09 Apr 2018

BRIEF-Celsion Corporation Provides Corporate Update And 2018 Outlook

* CELSION CORPORATION PROVIDES CORPORATE UPDATE AND 2018 OUTLOOK

18 Jan 2018

BRIEF-Celsion Announces FDA Clearance Of The OVATION II Study For The Evaluation Of GEN-1 Immunotherapy

* CELSION ANNOUNCES FDA CLEARANCE OF THE OVATION II STUDY FOR THE EVALUATION OF GEN-1 IMMUNOTHERAPY TO TREAT NEWLY DIAGNOSED STAGE III/IV OVARIAN CANCER

04 Jan 2018

Earnings vs. Estimates